Orasis is led by a collaborative team of expert industry executives and ophthalmologists
with a diverse set of experiences in ophthalmic drug development, ophthalmology
research, finance, and business development.
Chief Executive Officer
Elad Kedar has nearly 20 years of executive experience in the pharmaceutical industry, developing and growing healthcare organizations. His experience includes holding a variety of senior positions across different geographic locations and business environments, such as CFO of Eli Lilly South-East Europe and founder of PharmaSwiss Israel. Mr. Kedar brings his leadership and expertise to all stages of the pharmaceutical life cycle, from clinical development to commercialization.
Mr. Kedar holds an MBA from INSEAD and a B.A. in accounting and law from Tel Aviv University.
RON NEUMANN, M.D.
Chief Medical Officer
Dr. Ron Neumann has more than 30 years of experience as an ophthalmologist and working in the pharmaceutical industry. He has held many leading roles in clinical development and marketing, such as serving as the head of ophthalmology at Teva Pharmaceutical Industries. Dr. Neumann currently works as an advisor in the field of ocular drug development. He is also the chairperson for ISOPT Clinical (The International Symposium on Ocular Pharmacology and Therapeutics).
Dr. Neumann holds an M.D. in ocular immunology from Massachusetts Eye and Ear Infirmary. He completed his fellowship program in inflammatory eye diseases at Harvard University.
Head of Pharmaceutical Development and Manufacturing
Sharon Amzel-Sasson is a development and operations executive with 15 years of experience leading drug development (CMC) and project management teams in the biomedical industry, both in large multinational corporations as well as in startup environments. Ms. Amzel-Sasson is an expert in the development and manufacturing of pharmaceutical drugs and drug-device combination products, with extensive expertise in ophthalmic and sterile products.
Ms. Amzel-Sasson holds an MBA from Tel Aviv University and a B.S. in biotechnology and food engineering from the Technion – Israel Institute of Technology.
Head of Finance and Business Development
Julia Reznick is a finance and business development executive with more than 18 years of experience in the pharmaceutical industry. Her recent roles include senior positions at Teva Pharmaceutical Industries, where she led multinational teams in R&D, finance, and commercialization for innovative products. Ms. Reznick has a broad range of expertise in various types of business development deals and M&A activities.
Ms. Reznick holds an MBA and a B.A. in economics and business management from Tel Aviv University.
Director, US Clinical Operations
Cam Dang is a clinical research professional with more than 15 years of clinical operations experience in the biopharmaceutical industry. During this time, her expertise spans over a variety of Therapeutic Areas, with a focus in Ophthalmology. In her recent role, she served as Senior Clinical Trials Manager at Allergan, Inc. and has led the execution of regional and global clinical studies, ranging from Phase 1-3 study initiation, on-going study management, through study close out.
Ms. Dang holds B.A. in Liberal Studies emphasizing in Psychology from California State Polytechnic University and she is a Certified Clinical Research Associate.